Advertisement
Advertisement
U.S. markets open in 6 hours 41 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Hillstream BioPharma, Inc. (HILS)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.9100-0.0200 (-2.15%)
At close: 02:28PM EDT
0.9400 +0.03 (+3.30%)
After hours: 04:36PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close0.9300
Open0.9300
Bid0.0000 x 1000
Ask0.0000 x 1000
Day's Range0.9000 - 0.9300
52 Week Range0.8920 - 4.2400
Volume25,951
Avg. Volume333,677
Market Cap10.342M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3970
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for HILS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Hillstream BioPharma, Inc.
    Daily – Vickers Top Insider Picks for 05/19/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Hillstream BioPharma to Present at BioNJ's 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022

    Developed in partnership with J.P. Morgan and Johnson & Johnson Innovation, the Conference will bring together more than 500 life sciences professionals and thought leadersHillstream’s presentation will feature its flagship treatment, HSB-1216, which targets solid tumors as a ferroptosis-inducing agent and has shown a 71% response rate and efficacy against devastating cancers in a clinical study pilot BRIDGEWATER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ: HILS) (

  • GlobeNewswire

    Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers

    HSB-1216’s active moiety in clinical pilot study produced a 71% response rate in TNBC and epithelial carcinomasHSB-1216 was recently granted Orphan Drug Designation to treat Uveal Melanoma by the FDARare Pediatric Disease (RPD) Designation and Orphan Drug Designation was granted to HSB-888’s active moiety for pediatric osteosarcoma by the FDAReplay of R&D Day webcast available on Hillstream’s IR site BRIDGEWATER, NJ, March 02, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ: HILS) ("

  • GlobeNewswire

    Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma

    -Uveal melanoma is an aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease- -Evidence implicates ferroptosis, an emerging iron-mediated cell death, as a pathway to effectively eradicate uveal melanoma in proof-of-concept animal models -HSB-1216, a novel ferroptosis inducer against solid tumors has been granted an Orphan Drug Designation for the treatment of uveal melanoma by the US FDA Bridgewater, NJ, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Hills

Advertisement
Advertisement